Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer.

doi:10.1007/s00280-026-04953-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer.

Cancer chemotherapy and pharmacology - 17 Sept 2026

Ozbay Mehmet Fatih, Atlım Fikret, Vurgun Sertac, Hunur Mehmet, Keven Ayse, Sahin Eren, Göksu Sema Sezgin, Karaca Mustafa

Abstract excerpt

PURPOSE: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a cornerstone of metastatic colorectal cancer treatment. While systemic hypertension is a recognized complication of VEGF pathway inhibition, the effects of bevacizumab on the pulmonary vasculature remain poorly characterized, and the only longitudinal CT data to date derive from hepatocellular carcinoma patients...

Read the complete abstract on PubMed

Topics

Humans
Bevacizumab
Male
Pulmonary Artery
Retrospective Studies
Female

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Colonic Neoplasms

Middle Aged

Aged

Proto-Oncogene Proteins p21(ras)

Mutation

Tomography, X-Ray Computed

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Source

Open in PubMed

Identifiers

PMID: 42752894
DOI: 10.1007/s00280-026-04953-2

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer.PMID 42752894Read ↗

Deciphering Colorectal Liver Metastasis Perfusion Heterogeneity: Identification of Distinct Vascular Phenotypes through High-Lateral-Resolution Photoacoustic Microscopy.Semantic proximity Read ↗

Postmortem Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Metastatic NTRK Gene Fusion-Positive Transverse Colon Cancer During Effective Entrectinib TreatmentSemantic proximity Read ↗

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.Semantic proximity Read ↗

Prognostic impact of spread through air spaces and its association with KRAS mutation and histopathologic factors in resected colorectal lung metastases.Semantic proximity Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

Pembrolizumab plus bevacizumab achieves long-term progression free survival in patients with lung adenocarcinoma with brain metastases: a case report and literature reviewSemantic proximity Read ↗

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.